AbbVie's Upadacitinib Safety Appears Improved In Largest, Longest RA Study

 
• By Mandy Jackson

AbbVie's JAK1 inhibitor upadacitinib bested the company's blockbuster Humira in the largest and longest trial to date – on both efficacy and safety – perhaps alleviating concerns about cardiovascular events.

two hands trying to connect couple puzzle piece with sunset background. Jigsaw alone wooden puzzle against sun rays. one part of whole. symbol of association and connection. business strategy.

More from Clinical Trials

More from R&D